Evaluation of a Wearable Device for Acute Treatment of Migraines
Launched by HINGE HEALTH, INC · Jun 3, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new wearable device designed to help relieve migraine pain. Participants will wear this device on their forehead or the back of their neck to see if it can effectively reduce their migraine symptoms compared to a fake treatment that does not provide any real relief. The researchers want to find out if this device can be a helpful option for those suffering from migraines, which can be very painful and disruptive.
To be eligible for the study, participants must be at least 18 years old, have a diagnosis of migraine with or without aura, and typically experience moderate to severe migraine pain. They should have had migraines for at least a year and average two or more migraines each month. Participants will need to use the device as their first treatment option for migraines during the study and will be asked not to change their current migraine medications. The study is currently not recruiting participants, but it aims to provide new insights into non-invasive treatments for migraine relief.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of migraine with or without aura, identified via participant-provided medical records.
- • Average migraine pain is 4 or more on the 0-10 Numerical Rating Scale (NRS) for pain.
- * Passes ID-Migraine pre-screening questions and has ID-Migraine score ≥ 2:
- • a. ID-Migraine pre-screening questions: i. How many headaches have participants experienced within the previous 3 months?
- • Needs to be ≥ 6 headaches ii. Do the headaches that participants experience limit the ability to work, study, or enjoy life, or does the participant wish to speak with a healthcare professional about the headaches? (yes / no)
- • Participant needs to respond "yes" b. ID-Migraine questions: i. Over the last 3 months, did participants have any of the following with headaches?
- • Felt nauseated or sick to stomach (yes \[1\] / no \[0\])
- • Light bothered them (a lot more than when headaches are not present)? (yes \[1\] / no \[0\])
- • Headaches limited the ability to work, study, or do what needed to be done? (yes \[1\] / no \[0\])
- • Able to understand and provide informed consent.
- • Age 18 and older.
- • US resident.
- • Has experienced migraines for at least 1 year prior to recruitment.
- • Onset of migraines occurred at age 50 years or younger.
- • Average of at least 2 migraines per month of moderate to severe intensity.
- • Is either on a) no medications or b) a stable dose of migraine-preventative medication for at least 2 months prior to recruitment.
- • Willing to refrain from altering preventive medication for migraines (or from using botox), commit to using Enso as the first-line treatment, and wait at least 2 hours after Enso treatment before using any additional abortives during the study period.
- • Participants must own an iPhone with iOS 15 or newer, or an Android phone with Android 9 or newer, with Bluetooth capability and access to either the Apple App Store (for iOS devices) or Google Play Store (for Android devices).
- • Has an email account.
- Exclusion Criteria:
- • Typical migraine pain is \< 4 out of 10 on the 0-10 NRS.
- • Currently institutionalized.
- • Currently is or has ever been a Hinge Health member.
- • Use of antipsychotic medication up to 3 months before study recruitment.
- • Diagnosis of cancer/malignant tumors in the last 5 years.
- • Cognitive, behavioral, neurologic, or psychiatric disorder (e.g., dementia, Parkinson's, schizophrenia, stroke) that may interfere with the study or prevent the subject from complying with the requirements of the protocol.
- • Has epilepsy.
- • Has a history of major cardiovascular events such as strokes, arrhythmias, or myocardial infarction.
- • Has a history of major migraine complications such as migrainous infarction or migraine aura-triggered seizure
- • Diagnosed with secondary headache disorders including medication overuse headaches
- • History of opioid, alcohol, or drug abuse in the last 1 year.
- • Has a cardiac pacemaker, implanted defibrillator, spinal cord stimulator, pain pump, insulin pump, or any other implanted electronic device.
- • Has a metal implant in the upper extremities or head.
- • Has a history of major head or neck surgeries.
- • Pregnant.
- • Currently participating or has participated in a study with an investigational compound or device within the last 30 days before the screening visit.
- • Currently using a TENS device to treat migraines.
- • Received supraorbital nerve blocks or Botox treatment within 4 months prior to recruitment.
- • Insufficient proficiency with the English language to take part in study procedures or complete online surveys.
- • Planning to travel outside of the US within three months after consenting to the study.
About Hinge Health, Inc
Hinge Health, Inc. is a leading digital health company focused on transforming musculoskeletal care through innovative technology and evidence-based solutions. By leveraging a combination of wearable sensors, personalized exercise therapy, and comprehensive educational resources, Hinge Health aims to enhance patient outcomes, reduce healthcare costs, and improve overall quality of life for individuals suffering from chronic pain and related conditions. Committed to advancing research and clinical practices, the company actively sponsors clinical trials to validate the efficacy of its digital programs and contribute to the growing body of knowledge in the field of musculoskeletal health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mallika Bariya, PhD
Principal Investigator
Hinge Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported